Insys Therapeutics Company Profile (NASDAQ:INSY)

Analyst Ratings

Consensus Ratings for Insys Therapeutics (NASDAQ:INSY) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $25.80 (62.88% upside)

Analysts' Ratings History for Insys Therapeutics (NASDAQ:INSY)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016Piper Jaffray Cos.Reiterated RatingOverweight$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2016Janney Montgomery ScottInitiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Royal Bank Of CanadaReiterated RatingOutperform$44.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Jefferies GroupLower Price TargetBuy$23.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Insys Therapeutics (NASDAQ:INSY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215$0.21$0.21$74.06 million$77.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115$0.35$0.63$70.90 million$70.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214$0.30$0.58$52.77 million$55.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114$0.28$0.23$45.63 million$41.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Insys Therapeutics (NASDAQ:INSY)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.05$0.05$0.05
Q2 20161$0.04$0.04$0.04
Q3 20161$0.10$0.10$0.10
Q4 20161$0.14$0.14$0.14
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Insys Therapeutics (NASDAQ:INSY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Insys Therapeutics (NASDAQ:INSY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Insys Therapeutics (NASDAQ:INSY)
DateHeadline
07/26/16 03:24 PMInvestors Are Betting Big Against Insys Therapeutics -- Here's Why You Shouldn't -
07/26/16 07:38 AMInsys Therapeutics (INSY) Shares are Up 6.48% – Trade Calls - Trade Calls
07/22/16 04:36 PMFirms and Funds Increasing Their Stake in INSYS Therapeutics, Inc. (NASDAQ:INSY) - Engelwood Daily
07/22/16 07:35 AMEarnings Focus and Crowd Sourced Sentiment Review for Insys Therapeutics, Inc. (NASDAQ:INSY) - TGP
07/21/16 04:48 PMStock Marching Up in Session: INSYS Therapeutics, Inc. (NASDAQ:INSY) - TGP
07/21/16 04:48 PMInsys Therapeutics Inc's Big Gap Up Today Points to Less Stock Risks - Press Telegraph
07/21/16 10:42 AMInsys Therapeutics to Report Second Quarter 2016 Results - GlobeNewswire (press release)
07/21/16 10:42 AMINSYS Therapeutics Inc versus Intrexon Corporation Head to Head Compare - CML News
07/20/16 03:30 PMInsys Therapeutics to Report Second Quarter 2016 Results - [GlobeNewswire] - PHOENIX, July 20, 2016-- Insys Therapeutics, Inc. today announced that the Company will release its financial results for the second quarter 2016 on Wednesday, August 3, 2016, before the U.S. financial ...
07/20/16 03:20 PMThis Marijuana Drugmaker Sets Its Sights on a 9-Figure Market -
07/19/16 04:46 PMShares Lower on the Year INSYS Therapeutics, Inc. (NASDAQ:INSY) - Press Telegraph
07/19/16 04:46 PMEnanta Pharmaceuticals Inc versus INSYS Therapeutics Inc Head to Head Compare - CML News
07/19/16 08:04 AMHow Do Healthcare Companies Market Their Products? -
07/18/16 09:55 AMShares Moving Down on the Week: INSYS Therapeutics, Inc. (NASDAQ:INSY) - Engelwood Daily
07/18/16 09:55 AMStock in Positive Territory for the Quarter: INSYS Therapeutics, Inc. (NASDAQ:INSY) - Engelwood Daily
07/18/16 09:55 AMShare Performance Summary for: INSYS Therapeutics, Inc. (NASDAQ:INSY) - Press Telegraph
07/18/16 09:55 AMHow Analysts Rated Insys Therapeutics Inc (NASDAQ:INSY) Last Week? - Consumer Eagle
07/18/16 07:30 AMPharmaceutical Studies & Trials of Individual Cannabinoids Aim to Develop Cannabis Strains That Specifically Target Cancer Pain and Nausea - [CNW Group] - Pharmaceutical Studies & Trials of Individual Cannabinoids Aim to Develop Cannabis Strains That Specifically Target Cancer Pain and Nausea
07/15/16 08:17 AMInsys Therapeutics Incorporated (NASDAQ:INSY) Sellers Increased By 1% Their Shorts - Consumer Eagle
07/15/16 08:17 AMInstitutions are Increasing Positions in INSYS Therapeutics, Inc. (NASDAQ:INSY) - Engelwood Daily
07/14/16 04:50 PMInsys Therapeutics, Inc. (INSY) Current Analyst Ratings - Fiscal Standard
07/13/16 05:03 PMA Reversal for Insys Therapeutics Inc Is Not Near. The Stock Declines Again - Consumer Eagle
07/13/16 07:35 AMShares Losing Ground for the Month; Investor Alert on INSYS Therapeutics, Inc. (NASDAQ:INSY) - Engelwood Daily
07/12/16 04:55 PMTrading Performance and Target Watch for Insys Therapeutics, Inc. (NASDAQ:INSY) - Press Telegraph
07/11/16 04:43 PMInsys Therapeutics, Inc. (NASDAQ:INSY) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 04:43 PMStock Performance Rundown on: INSYS Therapeutics, Inc. (NASDAQ:INSY) - Press Telegraph
07/11/16 09:21 AMSyndros Approved for AIDS-Related Anorexia
07/08/16 07:31 AMWall Street Ratings and Target Price Views on Insys Therapeutics, Inc. (NASDAQ:INSY) - Telanagana Press
07/08/16 07:31 AMShort Information Review for: INSYS Therapeutics, Inc. (NASDAQ:INSY) - Engelwood Daily
07/07/16 04:43 PMPiper Jaffray On FDA Approval Of Insys Therapeutics' Anorexia Drug Syndros
07/07/16 07:33 AMStock Expected to Grow at an Accelerated Rate: INSYS Therapeutics, Inc. (NASDAQ:INSY) - Telanagana Press
07/07/16 07:33 AMINSYS Therapeutics, Inc. Stock Momentum at Critical Inflection Point - CML News
07/07/16 07:33 AMInsiders Increasing Positions in: INSYS Therapeutics, Inc. (NASDAQ:INSY) - Press Telegraph
07/07/16 07:33 AMWhen Is Insys Therapeutics Inc. (NASDAQ: INSY) Launching Newly-Approved Syndros? - Scibility Media
07/06/16 04:55 PMFDA Clears Oral Cannabis Drug for AIDS, Cancer Patients
07/06/16 04:55 PMPhoenix pharma firm gets FDA nod on cannabis treatment; sends stock soaring
07/06/16 09:18 AMHC Stocks Assessment: Boston Scientific Corporation (NYSE:BSX), Insys Therapeutics Inc (NASDAQ:INSY) - share market updates (press release)
07/06/16 09:18 AMBRIEF-Insys Therapeutics announces FDA approval of Syndros - Reuters
07/06/16 09:18 AMTuesday Morning's Market Insights: Tesla Motors Inc (TSLA), Amedica Corporation (AMDA), Insys Therapeutics Inc ... - Smarter Analyst
07/06/16 09:18 AMStock Rating Watch and Earnings Insight for Insys Therapeutics, Inc. (NASDAQ:INSY) - Press Telegraph
07/06/16 09:18 AMEye Catching Stock: INSYS Therapeutics, Inc. (NASDAQ:INSY) - News Oracle
07/06/16 09:18 AMInvestigation of INSYS Therapeutics Inc. - Pharmaceutical Processing
07/06/16 09:18 AMInsys Therapeutics Announces FDA Approval of Syndros™ - Yahoo Finance
07/06/16 09:18 AMInsys Therapeutics Inc. (INSY) Jumps 8.31% on July 05 - Equities.com
07/05/16 04:30 PMINSYS Therapeutics (INSY) Jumps on FDA Approval of Cannabis-based Drug
07/05/16 09:16 AMInsys Therapeutics' (INSY) Syndros Approved by FDA
07/05/16 09:16 AMInsys Therapeutics Announces FDA Approval of Syndros™
07/05/16 09:16 AMINSYS Therapeutics Inc. (INSY) Is Up Sharply After FDA Approves Syndros
07/05/16 08:16 AMInsys's stock soars after cannabis-based oral drug gets FDA approval -
07/05/16 07:40 AMInsys Soars on Huge FDA Win -

Social

About Insys Therapeutics

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INSY
  • CUSIP:
Key Metrics:
  • Previous Close: $15.79
  • 50 Day Moving Average: $14.28
  • 200 Day Moving Average: $16.13
  • P/E Ratio: 22.41
  • P/E Growth: 1.57
  • Market Cap: $1.11B
  • Beta: 2.01
  • Current Year EPS Consensus Estimate: $0.36 EPS
  • Next Year EPS Consensus Estimate: $0.87 EPS
Additional Links:
Insys Therapeutics (NASDAQ:INSY) Chart for Wednesday, July, 27, 2016